Definium Therapeutics
DFTX
152 hedge funds and large institutions have $299M invested in Definium Therapeutics in 2024 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 39 increasing their positions, 24 reducing their positions, and 26 closing their positions.
282% more call options, than puts
Call options by funds: $14.4M | Put options by funds: $3.77M
84% more capital inflows, than outflows
Capital inflows: $122M | Capital outflows: $66.7M
73% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 26
63% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 24
13% more funds holding
Funds holding: 134 → 152 (+18)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
26.45% less ownership
Funds ownership: 84.24% → 57.8% (-26%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$40.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$14.7M |
| 3 |
Commodore Capital
New York
|
+$11.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.3M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$18.8M |
| 2 |
Janus Henderson Group
London,
|
-$8.11M |
| 3 |
Soleus Capital Management
Greenwich,
Connecticut
|
-$7.05M |
| 4 |
Deep Track Capital
Greenwich,
Connecticut
|
-$4.92M |
| 5 |
Millennium Management
New York
|
-$3.65M |
DFTX Hedge Fund Activity: Q2 2024 in Review
152 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q2 2024, worth a combined $299M — down 8.6% from $327M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new DFTX positions and 26 closed out — a net gain of 19 holders — while 39 added to existing stakes and 24 trimmed.
The largest buyer was BlackRock, adding an estimated $40.1M. The largest seller was Great Point Partners, exiting entirely with an estimated $18.8M sold.
- 152 institutional investors held Definium Therapeutics (DFTX) as of Q2 2024, up from 134 in Q1 2024.
- Funds reported $299M of Definium Therapeutics stock for Q2 2024, down 8.6% quarter-over-quarter.
- 45 funds opened new Definium Therapeutics positions in Q2 2024 and 26 closed out, a net change of +19 holders.
- The largest Definium Therapeutics buyer in Q2 2024 was BlackRock, an estimated $40.1M added.
- The largest Definium Therapeutics seller in Q2 2024 was Great Point Partners, an estimated $18.8M sold.
Based on aggregated 13F filings for Q2 2024.